 JERSEY CITY, N.J., July 14, 2022 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from the CANDLE 304s nested sub-study of ibrexafungerp for prevention of recurrent vulvovaginal candidiasis RVVC will be presented during the International Society for the Study of Vulvovaginal Disease ISSVD XXVI World Congress and International Vulvovaginal Disease Update being held in Dublin, Ireland, July 15-20, 2022. 